|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|5.||Lung Neoplasms (Lung Cancer)
|1.||Pass, Harvey I: 68 articles (12/2015 - 02/2002)|
|2.||Carbone, Michele: 57 articles (12/2015 - 02/2002)|
|3.||Nakano, Takashi: 57 articles (12/2015 - 09/2006)|
|4.||Sugarbaker, David J: 44 articles (05/2015 - 05/2002)|
|5.||Mutti, Luciano: 43 articles (12/2015 - 02/2002)|
|6.||Bueno, Raphael: 38 articles (05/2015 - 05/2002)|
|7.||Creaney, Jenette: 37 articles (07/2015 - 11/2003)|
|8.||Hassan, Raffit: 36 articles (12/2015 - 11/2002)|
|9.||Robinson, Bruce W S: 36 articles (05/2015 - 02/2002)|
|10.||Kishimoto, Takumi: 34 articles (10/2015 - 04/2003)|
|1.||Cisplatin (Platino)FDA LinkGeneric
01/01/1991 - "[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy]."
06/01/2010 - "Since it has been recently suggested that Mcl-1 cooperates with Bcl-x(L) for protection against cell death, we investigated the response of mesothelioma cell lines to the downregulation of Bcl-x(L) (alone or in combination with cisplatin) and the potential interest of its concomitant inhibition with that of Mcl-1. "
02/01/2013 - "The findings of the present study provide insights into cisplatin-induced mechanisms in mesothelioma cells and show that alternative pathways are operating which may provide new options for targeting this extremely resistant tumour."
02/01/2013 - "In this study, we examined cisplatin-induced cell death pathways and IAPs in three mesothelioma-derived cell lines. "
03/01/2010 - "This study aims to investigate the effect of intrapleural polymeric films containing cisplatin on the local recurrence of malignant pleural mesothelioma in a rat tumour model. "
|2.||pemetrexed (MTA)FDA Link
04/01/2013 - "Pemetrexed has been approved with an anti-mesothelioma drug and was confirmed to be effective for NSCLC. "
10/01/2009 - "Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort."
11/15/2002 - "Pemetrexed is a novel antifolate effective in the treatment of mesothelioma. "
04/15/2003 - "This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). "
05/01/2012 - "In our institution, the MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal malignant mesothelioma. "
01/01/2013 - "Malignant mesothelioma is an asbestos-related fatal disease with no effective cure. "
04/02/2010 - "Malignant mesothelioma is an asbestos-related fatal disease with no effective cure. "
01/01/2009 - "There is no effective cure or treatment for any of the lung or pleural asbestos related diseases; malignant mesothelioma has a median survival of just 6-12 months. "
08/01/1995 - "Most malignant mesothelioma cases are associated with pulmonary asbestos body (AB) counts significantly greater than those of the general population. "
08/15/2008 - "Some authors have suggested that the increase in mesothelioma rate with TSFE might be attenuated by clearance of asbestos from the lungs. "
05/01/2012 - "It was found through a case-series study that platinum pharmaceutical plus antimetabolite are effective against peritoneal malignant mesothelioma. "
10/01/2013 - "In our open-label, single-arm, phase 2 study, we enrolled patients aged 18 years or older with measurable, unresectable malignant mesothelioma and progressive disease after a first-line platinum-based regimen. "
01/01/2014 - "We report the case of a biopsy proven Malignant Pleural Mesothelioma (MPM) presenting as an anterior mediastinal mass in a platinum miner. "
04/01/2012 - "Platinum-based therapy is widely used in the treatment of malignant mesothelioma (MM); however, the efficacy and toxicity of platinum agents vary greatly between patients. "
04/01/2012 - "The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma."
05/01/2006 - "The study showed that mesothelial marker antibodies commonly used in human patients can be used for the diagnosis of feline mesothelioma, preferably as a panel of antibodies rather than only one."
01/01/1995 - "Previous immunohistochemical studies on malignant mesothelioma with antibodies recognizing both the wild and the mutant types of the p53 protein have shown immunoreactivity in 25-70% of cases. "
10/01/1991 - "To determine the origin of a mesothelioma of the atrioventricular node, immunohistochemical studies that used various antibodies, including the antibody against mesothelial cells, were performed on a mesothelioma of the atrioventricular node in a case. "
01/01/2015 - "Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma."
11/01/2014 - "The certain morphological diagnosis of a malignant pleural mesothelioma requires the establishment of mesothelial differentiation by means of an appropriate panel of antibodies to exclude pleural dissemination of a pulmonary or extrapulmonary epithelial malignancy and also requires the establishment of at least focal invasive growth to distinguish from reactive mesothelial proliferation. "
08/01/2009 - "The administration of gemcitabine and doctaxel appears to be promising first-line therapy for patients with mesothelioma, as it is well tolerated and appears to improve survival."
04/01/2003 - "[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma]."
01/01/1999 - "Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine."
01/01/2012 - "The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). "
02/01/2002 - "The role of single-agent gemcitabine in patients with mesothelioma is unclear, since three phase II trials treated a total of 60 patients and achieved response rates of 0%, 7%, and 31%. "
10/20/2015 - "Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells."
01/01/2015 - "This study shows that mesothelioma promotes DC lipid acquisition, which is associated with altered activation status and reduced capacity to process and present antigens, which may impair the ability of DCs to generate effective anti mesothelioma T cell responses."
10/20/2015 - "Adoptive cell transfer experiments further demonstrated that antigen spreading-induced CD8+ T cells conferred efficacious therapeutic effects against established WT-AB1 mesothelioma and prevented the increase of exhausted PD-1+ and Tim-3+ CD8+ T cells. "
10/20/2015 - "Here, we further investigated the efficacy and correlation of protection on the model vaccine-mediated antigen spreading against wild-type AB1 (WT-AB1) mesothelioma. "
01/01/2015 - "There was positive immunohistochemical staining of mesothelioma-associated antigens. "
|8.||Doxorubicin (Adriamycin)FDA LinkGeneric
07/01/2011 - "Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy."
04/01/2006 - "In clinical development as a single agent in patients with malignant mesothelioma (MM), at 480 microg/m2 intravenously weekly, analysis of survival indicated prolonged periods of stable disease in Phase II trials and a potential survival benefit, compared with doxorubicin, in a small unpublished Phase III trial. "
01/01/2002 - "A phase II study of Doxil in mesothelioma was performed. "
08/01/2000 - "Phase II study of intravenous Doxil in malignant pleural mesothelioma."
06/01/2000 - "In a phase II study, the efficacy and toxicity of Caelyx was tested in previously untreated patients with malignant pleural mesothelioma. "
|9.||Carboplatin (JM8)FDA LinkGeneric
01/01/1986 - "Carboplatin, like most other cytotoxic drugs, is active only in a small minority of patients with mesothelioma, but its ability to achieve occasional good responses and frequent symptomatic relief, combined with low toxicity, may justify a short therapeutic trial in patients whose tumour is symptomatic."
01/01/1986 - "Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma."
03/01/2007 - "Key Words: Mesothelioma , Gemcitbine , Carboplatin."
10/01/2005 - "Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma."
09/01/2000 - "Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin."
10/01/1998 - "Among these, calretinin generated a great deal of interest, but the number of studies evaluating the practical use of calretinin immunostaining in the diagnosis of mesothelioma is limited, and the study results are controversial. "
01/01/2015 - "The mechanistic understanding of the function of calretinin and its putative implication in signaling pathways in normal mesothelial cells may help understanding its role during the processes that lead to mesothelioma formation and could possibly open new avenues for mesothelioma therapy, either by directly targeting calretinin expression or indirectly by targeting calretinin-mediated downstream signaling."
01/01/2015 - "Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis."
04/15/2014 - "We studied the expression of MIF and CD74 together with calretinin in specimens of malignant pleural mesothelioma (MPM), correlating their expression levels with clinico-pathologic parameters, in particular overall survival (OS). "
01/01/2014 - "Immunocytochemistry showed positivity for calretinin and WT-1.A diagnosis of right submandibular salivary gland involvement from mesothelioma was established, allowing an adequate treatment. "
|1.||Drug Therapy (Chemotherapy)
12/01/2011 - "Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. "
02/01/1998 - "This is a case report of complete remission of malignant peritoneal mesothelioma by combined chemotherapy."
02/01/1998 - "A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy."
02/15/1997 - "Chemotherapy and radiation have not proven effective in controlling malignant mesothelioma. "
11/15/1983 - "One patient with paratesticular mesothelioma metastatic to lungs entered complete remission for 8 months; his disease has relapsed but he is alive 32 months after initiation of chemotherapy. "
01/01/1995 - "Prophylactic radiotherapy is highly effective in preventing tumour seeding in mesothelioma."
01/01/2015 - "The surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial) is a suitably powered, multicentre, randomised controlled trial, designed to evaluate the efficacy of prophylactic radiotherapy within 42 days of pleural instrumentation in preventing the development of PTM in MPM. "
07/01/2015 - "To evaluate the efficacy of prophylactic radiotherapy at intervention sites in patients with malignant pleural mesothelioma (MPM). "
12/01/2015 - "Postoperative hemithoracic radiotherapy has been used to treat malignant pleural mesothelioma, but it has not been assessed in a randomised trial. "
01/01/2012 - "The purpose of the study was to evaluate the techniques and effectiveness of radiotherapy in malignant pleural mesothelioma. "
|3.||Pneumonectomy (Lung Volume Reduction)
04/01/2012 - "Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma."
06/01/2011 - "The question addressed was whether extrapleural pneumonectomy (EPP) is superior to supportive care in the treatment of patients with malignant pleural mesothelioma (MPM). "
08/01/2007 - "Extrapleural pneumonectomy (EPP) is an effective treatment of malignant pleural mesothelioma. "
10/01/2004 - "Extrapleural pneumonectomy with adjuvant therapy could be effective treatment for malignant pleural mesothelioma."
01/01/2004 - "Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma."
|4.||Heterologous Transplantation (Xenotransplantation)
08/01/2014 - "ESKM was more potent in vivo against JMN mesothelioma, and effective against SET2 AML and fresh ALL xenografts. "
01/01/1988 - "The combination of recombinant human alpha-interferon-2a and active chemotherapeutic agents is effective in mesothelioma xenografts."
08/01/2004 - "A human mesothelioma xenograft model was then developed to assess the efficacy of this molecule in vivo. "
03/01/1994 - "Studies also showed that the mesothelioma xenograft was fluence rate- and fluence-dependent while the rat tumour exposed to the same conditions demonstrated neither of these dependencies. "
11/01/1988 - "We believe that our experimental tumour model using the nude rat as a carrier of the xenograft will be useful for studies of human mesothelioma."
|5.||Palliative Care (Palliative Medicine)
05/01/2015 - "The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. "
05/01/2011 - "The question addressed was whether pleurectomy/decortication (P/D) is superior to palliative care in the treatment of patients with malignant pleural mesothelioma (MPM). "
06/01/2011 - "Two studies analysed palliative treatment in mesothelioma and reported a median survival of seven months and improvement in symptoms in 25% of patients at one-year post-treatment. "
01/01/2014 - "The aim of this trial is to assess whether regular early symptom control treatment provided by palliative care specialists can improve health related quality of life in patients newly diagnosed with mesothelioma. "
07/01/2009 - "Mesothelioma responds poorly to treatment and is almost always fatal, yet there have been few studies related to the palliative care needs of this diagnostic group and none focussing on the Latrobe Valley, Victoria, Australia. "